

Mirikizumab for treating moderately to severely active ulcerative colitis

Information for the public

Published: 25 October 2023

www.nice.org.uk

Mirikizumab (Omvoh) is available on the NHS. It is a possible treatment for adults with moderately to severely active ulcerative colitis if conventional or biological treatment is not tolerated, or it has not worked well enough. It is available if:

- a tumour necrosis factor (TNF)-alpha inhibitor has not worked well enough or
- a TNF-alpha inhibitor cannot be tolerated or is not suitable.

If you are not eligible for mirikizumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on ulcerative colitis](#) may be a good place to find out more.

[Crohn's and Colitis UK](#), 0300 222 5700, can give you advice and support.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5493-3